Activation of SUR2B/Kir6.1 subtype of adenosine triphosphate-sensitive potassium channel improves pressure overload-induced cardiac remodeling via protecting endothelial function

Journal of Cardiovascular Pharmacology

Volumn 56, Issue 4, 2010, Pages 345-353

  Tang, Yuan ^a,d   Long, Chao Liang ^a   Wang, Ru Huan ^b   Cui, Wenyu ^a   Wang, Hai ^a,b,c  

^a BEIJING INSTITUTE OF PHARMACOLOGY AND TOXICOLOGY   (China)

^b Thadweik Academy of Medicine   (China)

^c INSTITUTE OF HEALTH AND ENVIRONMENTAL MEDICINE   (China)

^d THIRD MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

ATP sensitive potassium channel; endothelial function; natakalim; pressure overload; SUR2B Kir6.1

Indexed keywords

ADENOSINE TRIPHOSPHATE SENSITIVE POTASSIUM CHANNEL; ATRIAL NATRIURETIC FACTOR; ENDOTHELIN 1; HYDROXYPROLINE; INWARDLY RECTIFYING POTASSIUM CHANNEL SUBUNIT KIR6.1; MESSENGER RNA; NATAKALIM; NATRIURETIC PEPTIDE RECEPTOR B; NITRIC OXIDE; NORADRENALIN; POTASSIUM CHANNEL STIMULATING AGENT; PROSTACYCLIN; UNCLASSIFIED DRUG; VASOACTIVE AGENT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD LEVEL; CONTROLLED STUDY; DRUG EFFECT; ENDOTHELIAL DYSFUNCTION; GENE EXPRESSION; HEART FAILURE; HEART LEFT VENTRICLE FUNCTION; HEART LEFT VENTRICLE HYPERTROPHY; HEART LEFT VENTRICLE MASS; HEART VENTRICLE OVERLOAD; HEMODYNAMIC PARAMETERS; HISTOLOGY; LUNG WEIGHT; MALE; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; RAT; TREATMENT DURATION; VASODILATATION;

ALLYL COMPOUNDS; ANIMALS; ATP-BINDING CASSETTE TRANSPORTERS; BLOOD PRESSURE; CARDIOMEGALY; CARDIOVASCULAR AGENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; ENDOTHELIAL CELLS; ENDOTHELIN-1; ENDOTHELIUM, VASCULAR; EPOPROSTENOL; HEART FAILURE; HYPERTENSION; MALE; MYOCARDIUM; NITRIC OXIDE; POTASSIUM CHANNELS, INWARDLY RECTIFYING; PROPYLAMINES; RATS; RATS, WISTAR; RECEPTORS, DRUG; TAIL; VASODILATOR AGENTS; VENTRICULAR REMODELING;

EID: 77958498187     PISSN: 01602446     EISSN: None     Source Type: Journal    
DOI: 10.1097/FJC.0b013e3181e6c7b8     Document Type: Article

References (34)

1. Miyamoto T, Takeishi Y, Takahashi H, et al. Activation of distinct signal transduction pathways in hypertrophied hearts by pressure and volume overload. Basic Res Cardiol. 2004;99:328-337.
2. Akki A, Smith K, Seymour AML. Compensated cardiac hypertrophy is characterised by a decline in palmitate oxidation. Mol Cell Biochem. 2008;311:215-224.
3. Ruetten H, Dimmeler S, Gehring D, et al. Concentric left ventricular remodeling in endothelial nitric oxide synthase knockout mice by chronic pressure overload. Cardiovasc Res. 2005;66:444-453.
4. Persoon-Rothert M, van der Wees KG, van der Laarse A. Mechanical overload-induced apoptosis: A study in cultured neonatal ventricular myocytes and fibroblasts. Mol Cell Biochem. 2002;241:115-124.
5. Hunter JJ, Chien KR. Signaling pathways for cardiac hypertrophy and failure. New Engl J Med. 1999;341:1276-1283.
6. AT P activation prevents progression of cardiac hypertrophy to failure induced by pressure overload via protecting endothelial function. Cardiovasc Res. 2009;83:444-456.
7. Wang H, Long CL, Duan ZB, et al. A new ATP-sensitive potassium channel opener protects endothelial function in cultured aortic endothelial cells. Cardiovasc Res. 2007;73:497-503.
8. + channels in rat aorta and brain microvascular endothelial cells. Am J Physiol. 1993;265: C812-C821.
9. + channels. Prog Biophys Mol Biol. 2003;81:133-176.
10. AT P channels. Chin Pharmacol Bull. 2006;22:284-287.
11. Minamino T, Hori M. Protecting endothelial function: a novel therapeutic target of ATP-sensitive potassium channel openers. Cardiovasc Res. 2007; 73:448-449.
12. Wang H, Tang Y, Zhang YL. Hypoxic pulmonary hypertension and iptakalim, a novel ATP-sensitive potassium channel opener targeting smaller arteries in hypertension. Cardiovasc Drug Rev. 2005;23:293-316.
13. Chen YP, Pan ZY, Cui WY, et al. Selectivity of new iptakalim derivatives on the subtypes of ATP-sensitive potassium channels. Chin Pharmacol Bull. 2008;24:1427-1430.
14. Chen YP, Qiu CR, Wang H. Cardiovascular pharmacological characterization of novel 2, 3-dimethyl-2-butylamine derivatives in rats. Life Sci. 2003;75:2131-2142.
15. Tang Y, Wang RH, Pan ZY, et al. The cardiovascular actions of natakalim, a highly selective opener of SUR2B/Kir6.1 subtype of ATP-sensitive potassium channels. Chin Pharmacol Bull. 2009;25:164-168.
16. Wang H, Tang Y, Wang L, et al. ATP-sensitive potassium channel openers and 2, 3-dimethyl-2-butylamine derivatives. Curr Med Chem. 2007;14: 133-155.
17. Liao Y, Takashima S, Asano Y, et al. Activation of adenosine A1 receptor attenuates cardiac hypertrophy and prevents heart failure in murine left ventricular pressure-overload model. Circ Res. 2003;93:759-766.
18. Jia GD, Liu GS, Wang H. Vasodilating characteristics of iptakalim hydrochloride. Med J Chin PLA. 2004;29:116-119.
19. Ghaleh B, Hittinger L, Kim SJ, et al. Selective large coronary endothelial dysfunction in conscious dogs with chronic coronary pressure overload. Am J Physiol. 1998;274:H539-H551.
20. John PB, Salah IM, Derek L, et al. Vitamin C and quinapril abrogate LVH and endothelial dysfunction in aortic-banded guinea pigs. Am J Physiol-Heart C. 2001;281:H1704-H1710.
21. McGoldrick RB, Kingsbury M, Turner MA, et al. Left ventricular hypertrophy induced by aortic banding impairs relaxation of isolated coronary arteries. Clin Sci. 2007;113:473-478.
22. Malo O, Desjardins F, Tanguay JF, et al. Tetrahydrobiopterin and antioxidants reverse the coronary endothelial dysfunction associated with left ventricular hypertrophy in a porcine model. Cardiovasc Res. 2003;59: 501-511.
23. Kim DJ, Park SH, Lim CS, et al. Cellular localization of integrin isoforms in phenylephrine-induced hypertrophic cardiac myocytes. Cell Biochem Funct. 2003;21:41-48.
24. Calderone A. The therapeutic effect of natriuretic peptides in heart failure: Differential regulation of endothelial and inducible nitric oxide synthases. Heart Fail Rev. 2003;8:55-70.
25. Kempf T, Wollert KC. Nitric oxide and the enigma of cardiac hypertrophy. Bioessays. 2004;26:608-615.
26. Schunkert H, Orzechowski HD, Böcker W, et al. The cardiac endothelin system in established pressure overload left ventricular hypertrophy. J Mol Med. 1999;77:623-630.
27. Turcani M, Rupp H. Bradykinin (B2) independent effect of captopril on the development of pressure overload cardiac hypertrophy. Mol Cell Biochem. 2000;212:219-225.
28. Kane GC, Behfar A, Dyer RB, et al. KCNJ11 gene knockout of the Kir6.2 KATP channel causes maladaptive remodeling and heart failure in hypertension. Hum Mol Genet. 2006;15:2285-2297.
29. Saavedra WF, Paolocci N, Kass DA. Effects of cardioselective KATP channel antagonism on basal, stimulated, and ischaemic myocardial function in in vivo failing canine heart. Brit J Pharmacol. 2002;135: 657-662.
30. Shi NQ, Ye B, Makielski JC. Function and distribution of the SUR isoforms and splice variants. J Mol Cell Cardiol. 2005;39:51-60.
31. AT P-channels in rat basilar and middle cerebral arteries: Studies of vasomotor responses and mRNA expression. Eur J Pharmacol. 2005;523:109-118.
32. Li L, Wu J, Jiang C. Differential expression of Kir6.1 and SUR2B mRNAs in the vasculature of various tissues in rats. J Membrane Biol. 2003;196: 61-69.
33. Schnitzler MM, Derst C, Daut J, et al. ATP sensitive potassium channels in capillaries isolated from guinea pig heart. J Physiol. 2000;525:307-317.
34. AT P channels of primary human coronary artery endothelial cells consist of a heteromultimeric complex of Kir6.1, Kir6.2, and SUR2B subunits. J Mol Cell Cardiol. 2004;37: 857-869.